Sanofi/Regeneron's Libtayo Pivotal Data Shines In Fourth Cancer Type
Phase III Trial In Cervical Cancer Stopped Early Due To Good OS Results
The Sanofi/Regeneron PD-1 inhibitor Libtayo has become the first immunotherapy to demonstrate an improved overall survival in patients with cervical cancer in a Phase III trial.
